AAA Study. Dr Antony Friedman IBD Fellow, The Alfred Hospital Melbourne, Australia
|
|
- Gabriel Hardy
- 5 years ago
- Views:
Transcription
1 AAA Study Use of Adjunctive Allopurinol in Azathioprine / 6-Mercaptopurine Non-Responders to Optimise 6-Thioguanine Nucleotide Production and Improve Clinical Outcomes Dr Antony Friedman IBD Fellow, The Alfred Hospital Melbourne, Australia
2 Background Historically many IBD patients fail thiopurine therapy due to resistance or intolerance Thiopurine remission rates of 30 60% Adjunctive allopurinol optimises thiopurine metabolism when given with reduced dose AZA / 6-MP Increasing 6-TGN levels Reducing 6-MMP levels Small retrospective case series to date 75% of patients achieve clinical remission This would allow > 15% more patients to tolerate and benefit from AZA / 6-MP which would represent a significant advance in IBD treatment
3 Traditional Thiopurine Metabolism 6-MMP 6-MMP 6-MeTIMP TPMT TPMT AZA 2.5mg/kg Glutathione 6-MP 1mg/kg XO 6-TA HPRT IMPDH GMPS 6-TIMP 6-TXMP 6-TIDP ITPase 6-TGN 6-TITP TPMT 6-MeTITP 6-TGMP 6-TGDP 6-TGTP
4 6-TGN Level Meta-Analysis Data Support the Correlation Between 6-TGN Levels and Clinical Response TGN level remission 6-TGN level active disease Odds Ratio remission if 6-TGN > = % C.I , p<0.001 Osterman MT et al. Gastroenterology 2006;130(4):
5 Recent Advances Ansari A et al, APT 2008; 28: TPMT 6-MMP >4,500 TPMT 6-MMP >4,500 6-MeTIMP Smith M et al, APT 2009; 30: Blaker PA et al, DDW 2011, Tu1214 AZA Glutathione 6-MP HPRT IMPDH GMPS 6-TIMP 6-TXMP 6-TGMP Allopurinol XO 6-TIDP ITPase 2-OH-6MP (6-TX) AO 6-TITP TPMT 6-TGN < TGDP 6-TA 6-MeTITP 6-TGTP
6 2-OH-6MP (6-TX) 2-OH-6MP (6-TX) 6-MMP <4,500 6-MMP <4,500 6-MeTIMP Ansari A et al, APT 2008; 28: Smith M et al, APT 2009; 30: Blaker PA et al, DDW 2011, Tu1214 TPMT TPMT AZA Glutathione 6-MP HPRT IMPDH GMPS 6-TIMP 6-TXMP 6-TGMP Allopurinol XO 6-TIDP ITPase 2-OH-6MP (6-TX) AO 6-TITP TPMT 6-TGN > TGDP 6-TA 6-MeTITP 6-TGTP
7 6-MMP pmol/l/hr 6-Thioxanthine Reduces 6-MMP Washed RBC from 8 healthy volunteers incubated with 6MP or 6MP + 6-TX, then lysed and 6-MMP measured p< MP 6MP + 2-OH6MP hours 4 hours Blaker PA et al, DDW 2011, Tu1214
8 TPMT - IU/ml 6-Thioxanthine Inhibits TPMT p=0.03 Blaker PA et al, DDW 2011, Tu1214
9 Aims 1. Prospectively reproduce these results in a clinical trial 2. To demonstrate that adjunctive allopurinol in patients otherwise producing 6-MMP increases the proportion of patients in clinical remission at 24 weeks 3. To demonstrate the safety of allopurinol-thiopurine combination therapy 4. To determine the optimal dose of allopurinol for this manoeuvre
10 Study Design Open to both Crohn s Disease (CD) and Ulcerative Colitis (UC) patients who meet the inclusion criteria Prospective study Double blind (to allopurinol dose) Dose-ranging, parallel group two arms: 50mg allopurinol with 25% of previous thiopurine dose 100mg allopurinol with 25% of previous thiopurine dose Randomised (to allopurinol dose) Interactive, web-based, randomisation schedule
11 Study Design Population: 76 patients (38 in each arm) Study timeline: 24 week study Wk 0, 2, 4, 8, 12 and 24) Safety/follow up visit at week 36 Sites: Melbourne: The Alfred Hospital, Box Hill Hospital, St Vincent s Hospital Adelaide: Flinders Medical Centre Brisbane: Mater Hospital UK: St Thomas s Hospital, London New Zealand: Christchurch Hospital
12 Inclusion Criteria Must fulfil all three of the following criteria: 1. Either steroid dependent OR not in clinical remission 2. Documented thiopurine shunter a. 6TGN < 260 and 6MMP > 4,500 b. 6TGN < 260 and 6MMP:6TGN ratio 20 c. 6TGN < 260 with hepatotoxcity (ALT 2 X ULN) 3. WCC 3.5 Not in clinical remission is defined as: > Harvey-Bradshaw Index (HBI) score 5 for CD > Simple Clinical Colitis Activity Index score 2 for UC
13 Primary Endpoint Steroid-free remission at 24 weeks Remission is defined as: HBI 4 for Crohn s Disease SCCAI 2 for Ulcerative colitis
14 Secondary Endpoints Disease Activity Comparison of the following values before and after the addition of allopurinol: disease activity indices corticosteroid dosages thiopurine metabolite levels TPMT phenotypic activity faecal calprotectin levels white cell count, CRP, LFTs Steroid-free remission at 12 weeks
15 Secondary Endpoints Safety & Tolerability Tolerability &safety of allopurinol-thiopurine combination: Leucopenic events (with/without sepsis) Hepatotoxicity from elevated 6TGN levels > Nodular regenerative hyperplasia and veno-occlusive disease Comparison of safety and efficacy data between allopurinol 50mg and 100 mg daily groups.
16 Study Progress Recruitment opened: April 2011 Total Enrolments: 10 patients Alfred: 7 Flinders: 2 St Vincent s: 1 Total Patients Completed: 2 Initial impressions at Week 12 (n = 5)... Non-analysed descriptive means
17 Allopurinol decreases thiopurine requirements and avoids leucopaenia 6MP Dose (mg) 80 Total WCC Screening Wk Wk 0 Wk 12
18 Allopurinol stops 6MMP production and increases 6TGN levels with decreased thiopurine dose 6TGN levels 6MMP levels Screening Wk Screening Wk 12
19 Combination therapy improves clinical scores for disease activity 6 HBI SCCAI Wk 0 Wk Wk 0 Wk 12
20 Combination therapy improves liver function and decreases inflammatory burden ALT (U/L) CRP Screening Wk 12 Wk0 Wk12
21 Interim Week 12 Biochemically effective: Reverses adverse thiopurine metabolite profile Improves LFTs Clinically effective: 4 of 5 patients in clinical remission Well tolerated: Self limiting mild nausea on initiation of allopurinol Safe: No episodes of leucopaenia No serious adverse events
22 Acknowledgements Broad Foundation AAA Study Sponsor Jo McKenzie Study Co-ordinator, The Alfred Hospital Dr Miles Sparrow & Prof Peter Gibson The Alfred Hospital A/Prof Peter Bamptom Flinders Medical Centre Dr Steven Brown St Vincent s Hospital Dr Alvin Chung Eastern Health Drs Paul Blaker & Jeremy Sanderson St Thomas s Hospital A/Prof Murray Barclay Christchurch Hospital Prof Tim Florin Mater Adult Hospital If anyone would like a copy of the slides or further information, please me at a.friedman@alfred.org.au
Allopurinol thiopurine combination therapy in inflammatory bowel disease
uer & herapy Allopurinol thiopurine combination therapy in inflammatory bowel disease Combination therapy with allopurinol and low-dose thiopurine (azathioprine and mercaptopurine) has been described as
More informationThe thiopurine immunomodulators azathioprine (AZA)
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:209 214 Effect of Allopurinol on Clinical Outcomes in Inflammatory Bowel Disease Nonresponders to Azathioprine or 6-Mercaptopurine MILES P. SPARROW,* SCOTT
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationPatient selection for azathioprine - typical courses of Crohn s disease
Patient selection for azathioprine - typical courses of Crohn s disease remitting 44% steroid refractory 20% remitting 48% steroid refractory 21% 36% steroid dependent 31% steroid dependent Munkholm et
More informationOptimizing Immunomodulators and
Optimizing Immunomodulators and Biologics i in Inflammatory Bowel Disease Sunanda Kane, MD, MSPH, FACG Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota,
More informationPART I OPPORTUNITIES AND THREATS OF THIOPURINE METABOLISM AND DRUG MONITORING
PART I OPPORTUNITIES AND THREATS OF THIOPURINE METABOLISM AND DRUG MONITORING CHAPTER 2 PHARMACOLOGICAL CONSIDERATIONS OF THIOPURINES IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE This chapter is an
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community.
More informationReview Article Immunomodulators and Immunosuppressants for Japanese Patients with Ulcerative Colitis
International Scholarly Research Network ISRN Gastroenterology Volume 2011, Article ID 194324, 5 pages doi:10.5402/2011/194324 Review Article Immunomodulators and Immunosuppressants for Japanese Patients
More informationUp to 50% of patients with inflammatory bowel disease
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:654 660 Thiopurine Dose in Intermediate and Normal Metabolizers of Thiopurine Methyltransferase May Differ Three-Fold SHARON J. GARDINER,*, RICHARD B. GEARRY,*,
More informationIncreased risk of morbidity associated with immunomodulator therapy
Increased risk of morbidity associated with immunomodulator therapy Jean-Frédéric Colombel, Murat Toruner CHU Lille, France University Medical School, Ankara, Turkey. Immunomodulators in IBD Earlier Longer
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More information6-Mercaptopurine (6-MP) and azathioprine (AZA) are
GASTROENTEROLOGY 2006;130:1047 1053 Association of 6-Thioguanine Nucleotide Levels and Inflammatory Bowel Disease Activity: A Meta-Analysis MARK T. OSTERMAN,*, RABI KUNDU, GARY R. LICHTENSTEIN,* and JAMES
More informationP de Graaf 1, NKH de Boer 2, DR Wong 3, S Karner 4, B Jharap 2, PM Hooymans 3, AI Veldkamp 1, CJJ Mulder 2, AA van Bodegraven 2 and M Schwab 4,5
British Journal of Pharmacology (2010), 160, 1083 1091 2010 The Authors Journal compilation 2010 The British Pharmacological Society All rights reserved 0007-1188/10 www.brjpharmacol.org RESEARCH PAPER
More informationBiomarkers and Thiopurines in Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) encompasses amongst others Crohn s disease (CD), ulcerative colitis (UC) and IBD unclassified (IBD-u). In the diagnostic algorithm of IBD, ileocolonoscopy plays a pivotal
More informationMEDICAL POLICY SUBJECT: GENOTYPING OR PHENOTYPING FOR THIOPURINE METHYLTRANSFERASE (TPMT) FOR PATIENTS TREATED WITH AZATHIOPRINE (6-MP)
MEDICAL POLICY SUBJECT: GENOTYPING OR PHENOTYPING PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
More informationCHAPTER 9. Efficacy of Thioguanine Treatment in Inflammatory Bowel disease: a Systematic Review
CHAPTER 9 Efficacy of Thioguanine Treatment in Inflammatory Bowel disease: a Systematic Review Berrie Meijer 1 Chris JJ Mulder 1 Godefridus J Peters 2 Adriaan A van Bodegraven 1,3 Nanne KH de Boer 1 8
More informationOptimizing treatment with thioguanine derivatives in inflammatory bowel disease
Optimizing treatment with thioguanine derivatives in inflammatory bowel disease Edouard Louis MD, PhD Jacques Belaiche MD, PhD Service de Gastroentérologie, CHU de Liège, 4000 Liège, Belgium Abstract Thioguanine
More informationWhen can I stop taking my medications? Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida
When can I stop taking my medications? Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Post-op low risk patient Uc de-escalation Discuss combo therapy Which one worked IBD
More informationClinical Use and Practical Application of TPMT Enzyme and 6-Mercaptopurine Metabolite Monitoring in IBD Ernest G. Seidman, MD
GENETIC TESTING FOR IBD Clinical Use and Practical Application of TPMT Enzyme and 6-Mercaptopurine Metabolite Monitoring in IBD Ernest G. Seidman, MD Division of Gastroenterology, Hepatology, and Nutrition,
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationNew treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
More informationPharmacogenomic and Metabolite Markers for Patients Treated with Thiopurines. Original Policy Date
MP 2.04.12 Pharmacogenomic and Metabolite Markers for Patients Treated with Thiopurines Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with
More informationEffect of Combination Therapy of Allopurinol and Reduced Dose of Azathioprine on Inflammatory Bowel Disease (IBD)
J. Basic. Appl. Sci. Res., 3(7)820-825, 2013 2013, TextRoad Publication ISSN 2090-4304 Journal of Basic and Applied Scientific Research www.textroad.com Effect of Combination Therapy of Allopurinol and
More informationThe Refractory Crohn s Disease
The Refractory Crohn s Disease Patient David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationWestern Locality Shared care information ~ Azathioprine and Mercaptopurine
The following guidelines are currently under review. In the interim, the guidelines remain valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they
More informationUvA-DARE (Digital Academic Repository)
UvA-DARE (Digital Academic Repository) On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients de Boer, N.K.H.; Derijks, L.J.J.;
More informationEndpoints for Stopping Treatment in UC
Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh
More informationMild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested. Philippe Marteau, Paris, France
Mild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested Philippe Marteau, Paris, France Sequential vs combined treatments When should one switch? Sequential vs combined treatments
More informationOPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG
1C: Advances in Inflammatory Bowel Disease OPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG narrow interpretation of this presentation topic would A be a discussion of dosing
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationDe uitgave van dit proefschrift is mogelijk gemaakt door een gift van Ferring B.V., Hoofddorp.
Thiopurines and IBD De uitgave van dit proefschrift is mogelijk gemaakt door een gift van Ferring B.V., Hoofddorp. Copyright 2007 K.H.N. de Boer, Amsterdam, The Netherlands No parts of this publication
More informationPharmacogenomic and Metabolite Markers for Patients Treated with Thiopurines
Last Review Status/Date: March 2017 Page: 1 of 12 for Patients Treated with Thiopurines Description The use of thiopurines, medications for treating inflammatory bowel disease (IBD) and other conditions,
More informationPrimary & Secondary Care Inflammatory Bowel Disease Pathway February 2018
South East London Area Prescribing Committee: Primary & Secondary Care Inflammatory Bowel Disease Pathway February 2018 Developed by: South East London IBD Pathway Development Group Approved: February
More informationLinköping University Post Print. How Should Thiopurine Treatment be Monitored? Methodological Aspects
Linköping University Post Print How Should Thiopurine Treatment be Monitored? Methodological Aspects Svante Vikingsson, Björn Carlsson, Sven Almer and Curt Peterson N.B.: When citing this work, cite the
More informationInflammatory bowel disease (IBD) Overview of the Paediatric investigation plans. Presented by: Richard Veselý. An agency of the European Union
Inflammatory bowel disease (IBD) Overview of the Paediatric investigation plans Presented by: Richard Veselý An agency of the European Union Adalimumab - Crohn s disease Indication: Treatment of severe,
More informationThiopurine S-Methyltransferase (TPMT): Pharmacogenetic Competency
Thiopurine S-Methyltransferase (TPMT): Pharmacogenetic Competency Updated on 6/2015 Pre-test Question # 1 Approximately 10% of patients have a (an) TPMT phenotype. a) Normal/high function b) Intermediate
More informationOptimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol
Journal of Crohn's and Colitis (2012) 6, 905 912 Available online at www.sciencedirect.com Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol Melissa A. Smith
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationTreating to Achieve a Target and Disease Monitoring in 2015: State of the Art
Treating to Achieve a Target and Disease Monitoring in 2015: State of the Art David T. Rubin, MD The Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationInflammatory Bowel Disease Drug Therapy 2016
Inflammatory Bowel Disease Drug Therapy 206 David T. Rubin, MD, FACG Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition Objectives Outline the goals of
More informationPublic Assessment Report. Scientific discussion. Thiosix 10 mg and 20 mg, tablets. (6-Thioguanine) NL License RVG
Public Assessment Report Scientific discussion Thiosix 10 mg and 20 mg, tablets (6-Thioguanine) NL License RVG 114680-114681 Date: 26 May 2015 This module reflects the scientific discussion for the approval
More informationCHAPTER 5. How I Treat my Inflammatory Bowel Disease-Patients with Thiopurines? 1 Department of Gastroenterology and Hepatology,
CHAPTER 5 How I Treat my Inflammatory Bowel Disease-Patients with Thiopurines? 4 Berrie Meijer 1 Chris JJ Mulder 1 Adriaan A van Bodegraven 1,2 Nanne KH de Boer 1 1 Department of Gastroenterology and Hepatology,
More informationPharmacogenomic and Metabolite Markers for Patients Treated with Thiopurines
Pharmacogenomic and Metabolite Markers for Patients Treated with Thiopurines Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationEfficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease
Online Submissions: wjg.wjgnet.com World J Gastroenterol 2008 July 21; 14(27): 4342-4346 wjg@wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 doi:10.3748/wjg.14.4342 2008 The WJG Press. All
More informationLatest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker
More informationProtocol. Pharmacogenomic and Metabolite Markers for Patients Treated With Thiopurines
Pharmacogenomic and Metabolite Markers for Patients Treated (20419) Medical Benefit Effective Date: 01/01/15 Next Review Date: 11/18 Preauthorization Yes Review Dates: 04/07, 09/08, 05/09, 03/10, 03/11,
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationLaboratory and Genetic Testing for use of Thiopurines
Medical Policy Manual Laboratory, Policy No. 70 Laboratory and Genetic Testing for use of Thiopurines Next Review: January 2019 Last Review: January 2018 Effective: March 1, 2018 IMPORTANT REMINDER Medical
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationAnti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis
Anti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis University, 1st Department of Medicine Budapest June 13-15,
More informationDavid Y. Graham, MD Baylor College of Medicine, Houston TX, USA
Phase III Randomized, Double Blind, Placebo- Controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Add-On Fixed-Dose Anti- Mycobacterial Therapy (RHB-104) in Moderately to
More information2nd Nottingham IBD Masterclass, 2017
2nd Nottingham IBD Masterclass, 217 Positioning IL12/IL23 blockade in the Crohn s disease treatment algorithm Prof James Lindsay, Consultant Gastroenterologist, Barts Health NHS Trust Professor in Inflammatory
More informationDr. Elmer Schabel, MD. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany (No conflicts of interest)
EMA workshop on the development of new medicinal products for the treatment of ulcerative colitis and Crohn s disease Overview of authorised medicines for IBD in Europe - previous regulatory positions
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationTherapeutic drug monitoring in patients with inflammatory bowel disease
Online Submissions: http://www.wjgnet.com/esps/ bpgoffice@wjgnet.com doi:10.3748/wjg.v20.i13.3475 World J Gastroenterol 2014 April 7; 20(13): 3475-3484 ISSN 1007-9327 (print) ISSN 2219-2840 (online) 2014
More informationShared Care Guideline
Shared Care Guideline Mercaptopurine inflammatory bowel disease Executive Summary Unlicensed indication, but widely established use of mercaptopurine. Dosing: 25mg daily for two weeks, then 1-1.5mg/kg
More informationThe Best of IBD at UEGW (Crohn s)
The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best
More information6-Thioguanine: efficacy and safety in the management of inflammatory bowel disease
6-Thioguanine: efficacy and safety in the management of inflammatory bowel disease Author A.S. Broeders a.s.broeders@student.rug.nl S1803778 Supervisor Dr. F. ter Borg Department Department of Gastroenterology
More informationBiologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
More informationTo help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture,
To help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture, click Options in the Message Bar, and then click Enable
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More information6-Thioguanosine Diphosphate and Triphosphate Levels in Red Blood Cells and Response to Azathioprine Therapy in Crohn s Disease
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1007 1014 6-Thioguanosine Diphosphate and Triphosphate Levels in Red Blood Cells and Response to Azathioprine Therapy in Crohn s Disease MARKUS F. NEURATH,*
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationAmine Benmassaoud, 1 Xuanqian Xie, 2 Motaz AlYafi, 1 Yves Theoret, 3 Alain Bitton, 1 Waqqas Afif, 1 and Talat Bessissow 1. 1.
Canadian Gastroenterology and Hepatology Volume 2016, Article ID 1034834, 7 pages http://dx.doi.org/10.1155/2016/1034834 Research Article Thiopurines in the Management of Crohn s Disease: Safety and Efficacy
More informationEDUCATION PRACTICE. Initiating Azathioprine for Crohn s Disease. The Problem. Clinical Scenario. Management Strategies Education
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:460 465 EDUCATION PRACTICE Initiating Azathioprine for Crohn s Disease BARRETT G. LEVESQUE* and EDWARD V. LOFTUS JR *Scripps Clinic, Division of Gastroenterology,
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationINFLAMMATORY BOWEL DISEASE
1. Medical Condition INFLAMMATORY BOWEL DISEASE (IBD) specifically includes Crohn s disease (CD) and ulcerative colitis (UC) but also includes IBD unclassified (IBDu), seen in about 10% of cases. These
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationEpidemiology of IBD in Pediatric Patients in the US: Data from the ImproveCareNow Registry
Epidemiology of IBD in Pediatric Patients in the US: Data from the ImproveCareNow Registry Michael D. Kappelman, MD Professor of Pediatrics and Epidemiology University of North Carolina, Chapel Hill Richard
More informationWithdrawal of drug therapy in patients with quiescent Crohn s disease
Withdrawal of drug therapy in patients with quiescent Crohn s disease DR. JEAN-FRÉDÉRIC COLOMBEL DIRECTOR OF THE IBD CENTER, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, USA Withdrawal of drug therapy
More informationGreater Manchester Interface Prescribing Group Shared Care Template
Greater Manchester Interface Prescribing Group Shared Care Template Shared Care Guideline for Azathioprine and 6-Mercaptopurine for Chronic Inflammatory Bowel Disease Author(s)/Originator(s): (please state
More informationPediatric Inflammatory Bowel Diseases
Pediatric Inflammatory Bowel Diseases Michael Stephens, M.D. Denny Sanford Pediatric Symposium November 21 2014, Sioux Falls, SD 2014 slide-1 Disclosures I have nothing to disclose 2014 slide-2 Objectives
More informationAvailable Data on Pediatric Exposure Response a Clinician s Perspective
Available Data on Pediatric Exposure Response a Clinician s Perspective Marla Dubinsky, MD Professor of Pediatrics and Medicine Chief Pediatric GI and Nutrition Co-Director Susan and Leonard Feinstein
More informationMaximizing the efficacy of therapies for inflammatory bowel
Therapeutic Drug Monitoring in Children and Young Adults With Inflammatory Bowel Disease: A Practical Approach Namita Singh, MD, and Marla C. Dubinsky, MD Dr Singh is an attending physician in the Pediatric
More informationIBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital
IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital Aims To understand the aetiology of IBD To understand the impact that
More information99 Chapter 8 Summary
99 Chapter 8 Summary 100 101 Summary Thiopurines are frequently used in the treatment of patients suffering from (auto)immune diseases. Since their introduction in the mid fifties of the 20 th century
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationDENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease
Measure #270: Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationPersonalized Medicine: IBD
Use of Anti-TNF Antibodies and Other Serologies for Managing IBD Christopher J. Shepela, MD, MS Assistant Professor of Medicine University of Minnesota Medical Director at Digestive Disease Center at Regions
More informationDavid Y. Graham, MD Baylor College of Medicine, Houston TX, USA
Phase III Randomized, Double Blind, Placebo- Controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Add-On Fixed-Dose Anti- Mycobacterial Therapy (RHB-104) in Moderately to
More informationSynopsis (C0168T37 ACT 1)
() Module 5.3 Protocol: CR004777 EudraCT No.: Not Applicable Title of the study: A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients with
More informationTreatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG
Treatment of Inflammatory Bowel Disease Michael Weiss MD, FACG What is IBD? IBD is an immune-mediated chronic intestinal disorder, characterized by chronic or relapsing inflammation within the GI tract.
More informationDrugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending
Policy Subject: Anti-TNF Agents Policy Number: SHS PBD16 Category: Rheumatology & Autoimmune Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationProtocol for the management of acute severe ulcerative colitis in children
Protocol for the management of acute severe ulcerative colitis in children Introduction: Paediatric UC is severe and more extensive than adult onset UC with 6-8% presenting as pancolitis (1,2) Within five
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationCrohn s Disease: The First Visit
Crohn s Disease: The First Visit Jack A. Di Palma, MD University of South Alabama Mobile, Alabama 1 Adverse Experiences Colombel, SONIC N Engl J Med 2010 Any Adverse Event Serious Adverse Event Azathioprine
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationLeucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide
656 Division of Gastroenterology, Division of Clinical Pharmacology, Department of Pharmacology, and Section of Biostatistics, Mayo Clinic, Rochester, MN, USA PWLowry C L Franklin ALWeaver C L Szumlanski
More informationGionata Fiorino VEDOLIZUMAB E IBD. Un nuovo target terapeutico
Gionata Fiorino VEDOLIZUMAB E IBD Un nuovo target terapeutico Anti cell adhesion molecules Danese S, NEJM 2011 6 Steps leukocyte recruitment Fiorino G. et al. 2010 Vedolizumab Blocks Fewer Biological Pathways
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationName of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008
Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008 Shared care agreement has been developed appropriately
More informationGenetic Screening for ADR
Genetic Screening for ADR Mahidol University Faculty of Medicine Siriraj Hospital Manop Pithukpakorn, MD Division of Medical Genetics Department of Medicine concentration Drug level over time toxic optimum
More informationSelection and use of the non-anti- TNF biological therapies: Who? When? How?
Selection and use of the non-anti- TNF biological therapies: Who? When? How? Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz Division of Gastroenterology The Icahn School of Medicine
More informationΑπό τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων
Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων Conflict of interest By means of this, the speaker confirms that
More informationClinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis
Clin Pharmacokinet https://doi.org/10.1007/s40262-018-0676-z REVIEW ARTICLE Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis Sophie E. Berends 1,2 Anne
More information